Posted by Michael Wonder on 26 Mar 2021
Highlights from the CHMP 22-25 March 2022 meeting
26 March 2021 - EMA’s CHMP recommended five medicines for approval at its March 2021 meeting.
The Committee recommended granting a marketing authorisation for Copiktra (duvelisib) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or refractory follicular lymphoma.
The CHMP adopted a positive opinion for Ponvory (ponesimod) for the treatment of active relapsing forms of multiple sclerosis.
